Congenital cytomegalovirus infection

European Journal of Obstetrics and Gynecology

Volumn 63, Issue 1, 1995, Pages 7-16

  Daniel, Yair ^a   Gull, Ilan ^a   Peyser, M Reuben ^a   Lessing, Joseph B ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Antenatal diagnosis; CMV; Pregnancy; Prenatal screening; Vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE;

CYTOMEGALOVIRUS INFECTION; FETUS; HEALTH CARE COST; HUMAN; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; UNITED STATES; VACCINATION;

EID: 0028867071     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0301-2115(95)02198-G     Document Type: Review

References (122)

1. The cytomegalovirus, ubiquitous agents with protein clinical manifestation
2. The cytomegalovirus, ubiquitous agents with protein clinical manifestation
3. Viral infections of the fetus and neonate
4. Congenital and perinatal cytomegalovirus infection
5. Prenatal diagnosis of fetal infection, advances from amniocentesis to cordocentesis — congenital toxoplasmosis, rubella, cytomegalovirus varicella virus, parvovirus and HIV
6. Effectiveness and cost benefit of proposed live cytomegalovirus vaccine in the prevention of congenital disease
7. Congenital cytomegalovirus infection — 20 years is long enough
8. Prospective study of cytomegalovirus in pregnancy
9. A prospective study of cytomegalovirus infection in pregnancy. I. Laboratory evidence of congenital infection following maternal primary and reactivated infection
10. A prospective study of primary cytomegalovirus infection in pregnant women
11. Epidemiological studies of congenital cytomegalovirus infection
12. Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus and clinical outcome
13. Herpes virus infections of pregnancy, part four
14. Cervical cytomegalovirus excretion in pregnant and nonpregnant women: suppression in early gestation
15. Factors predictive of cytomegalovirus immune status in pregnant women
16. Congenital and maternal cytomegalovirus infections in the London population
17. Sexually transmitted diseases in mothers of neonates with congenital cytomegalovirus infection
18. Cytomegalovirus
19. Maternal cytomegalovirus infection and perinatal transmission
20. Association of Cervical cytomegalovirus with venereal disease
21. Prevalence of cytomegalovirus infection in homosexual men
22. Factors associated with primary cytomegalovirus infection during pregnancy
23. Young children as a probable source of maternal and congenital cytomegalovirus infection
24. The natural history of aquired cytomegalovirus infection among children in group day care
25. Screening for viral and protozoan infections in pregnancy: a review
26. Child care workers and children with congenital cytomegalovirus infection
27. Cytomegalovirus transmission and child day care
28. Working parents: the impact of day care and breast-feeding on cytomegalovirus infections in offspring
29. Epidemiology of cytomegalovirus infections
30. The epidemiology of cytomegaloviral infection in women attending a sexually transmitted disease clinic
31. Cytomegalovirus infection in sex partners: evidence for sexual transmission
32. Epidemiology of cytomegaloviral infection in a heterogeneous population of pregnant women
33. Epidemiology and transmission of cytomegalovirus
34. Detection of human cytomegalovirus and analysis of strain variation
35. Comparative prevalence of subclinical cytomegalovirus in genital and urinary tracts of low-income urban women
36. Cytomegalovirus infeetion of breast milk and transmission in infancy
37. Congenital cytomegalovirus infection: occurrence in an immune population
38. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection
39. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status
40. Congenital and perinatal cytomegalovirus infection
41. Outcome of symptomatic congenital cytomegalovirus infection: results of long term longitudinal follow-up
42. Cytomegalovirus
43. Primary cytomegalovirus infection in pregnancy: comparison of antibody responses to virus-encoded proteins between women with and without intrauterine infection
44. Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus
45. Impaired cellular immunity to cytyomegalovirus in congenital infected children and their mothers
46. Specific cell-mediated immunity in children with congenital and neonatal cytomegalovirus infection and their mothers
47. Specific cell mediated immune defect in active cytomegalovirus infection of young children and their mothers
48. An early marker of fetal infection after primary cytomegalovirus infection in pregnancy
49. Lymphocyte responses and virus excretion as risk factors for intrauterine infection with cytomegalovirus
50. Cell types infected in human cytomegalovirus placentitis identified by immunohistochemical double staining
51. Epidemiology of cytomegalovirus
52. Congenital cytomegalovirus infection in newborn infants of mothers infected before pregnancy
53. Virological and clinical observations on cytomegalic inclusion disease
54. Congenital cytomegalic virus infection
55. Inapparent congenital cytomegalovirus infection a follow-up study
56. Congenital cytomegalovirus infection: developmental progress of infants detected by routine screening
57. The outcome in children with congenital cytomegalovirus infection: a longitudinal follow-up study
58. Inapparent congenital cytomegalovirus infection with elevated cord IGM levels: causal relationship with auditory and mental deficiency
59. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections
60. Antiviral antibody responses in mothers and their newborns with clinical and subclinical congenital cytomegalovirus infections
61. Maternal cytomegalovirus excretion and perinatal infection
62. Breast milk and the risk of cytomegalovirus infection
63. Cytomegalovirus in human milk
64. Prevention of transfusion acquired cytomegalovirus infection in newborn infants
65. Acquired cytomegalovirus infection in preterm infants
66. Infant pneumonitis associated with cytomegalovirus, chlamydia pneumocystis and ureaplasma: follow-up
67. Comparative serial virologic and serologic studies of symptomatic and subclinical congenital and natally acquired cytomegalovirus infection
68. Congenital and perinatal cytomegalovirus infection, clinical characteristics and pathogenic factors
69. Fluorescent-antibody test for cytomegalovirus macroglobulin
70. Comparative study of diagnostic procedures for congenital cytomegalovirus infection
71. Cytomegalovirus-infected cell polypeptides immune-precipitated by sera from children with congenital and perinatal infections
72. Specific lymphocyte blastogenic responses in children with cytomegalovirus and herpes simplex virus infections acquired early in infancy
73. Newer methods for diagnosis of cytomegalovirus infection
74. Infection with cytomegalovirus during pregnancy: specific IgM antibodies as a marker of recent primary infection
75. IgM antibodies detected by ELISA and RIA in the diagnosis of cytomegalovirus infections in pregnant women and newborn infants
76. Detection of human cytomegalovirus in urine samples by cell culture, early antigen assay and polymerase chain reaction
77. Perinatal infections and maldevelopment
78. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen
79. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens
80. Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early nuclear antigen
81. Detection of cytomegalovirus infections in specimens other than urine by the shell vial assay and conventional tube cell cultures
82. Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization
83. Detection of human cytomegalovirus in urine by DNA-DNA and RNA-DNA hybridization
84. Detection of human cytomegalovirus in clinical specimens by DNA-DNA hybridization
85. Viral diagnosis by in situ hybridization
86. Virus bacteria and protozoans in pregnancy a sample of each
87. Screening for congenital cytomegalovirus
88. Cytomegalovirus infections in pregnancy
89. Cytomegalovirus infection in pregnancy: preliminary findings from a prospective study
90. Cytomegalovirus and pregnancy
91. Cytomegalic inclusion disease: intrauterine sonographic diagnosis using findings involving the brain
92. Fetalabdominal echogenic mass: an early sign of intrauterine cytomegalovirus infection
93. Echogenic vessels in the fetal thalami and basal ganglia associated with cytomegalovirus infection
94. Cytomegalovirus mononucleosis in a first trimester pregnant female with transmission to the fetus
95. Prenatal diagnosis of fetal cytomegalovirus infection
96. Cytomegalovirus fetal infection
97. Use of monoclonal antibodies for the diagnosis of cytomegalovirus infection by detection of early antigen fluorescent foci in cell culture
98. Prenatal diagnosis of congenital cytomegalovirus infection by virus isolation following amniocentesis
99. Defects of tooth structure in congenital cytomegalovirus infection
100. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegalovirus and toxoplasma infections
101. Comparison of four serological tests for the detection of specific immunoglobulin M in the cord sera of infants congenitally infected with cytomegalovirus
102. Fetal cytomegalovirus infection
103. Prenatal diagnosis of congenital cytomegalovirus infection
104. Detection of congenital cytomegalovirus infection by using chorionic villi of the early pregnancy and polymerase chain reaction
105. Prenatal diagnosis of cytomegalovirus (CMV) infection: a preliminary report
106. Commentary
107. Prenatal diagnosis of 52 pregnancies at risk for congenital cytomegalovirus infection
108. Chronic intrauterine and perinatal infections
109. Treatment of serious cytomegalovirus infection with 9-(13-Dihydroxy-2-Propoxymethyl) guanine in patients with AIDS and other immunodeficiencies
110. Treatment of disseminated cytomegalovirus infection with 9-(13-Dihydroxy-2-Propoxymethyl) guanine Evidence of prolonged survival in patients with AIDS
111. UCLA CMV retinopathy study group treatment of cytomegalovirus retinopathy in patients with AIDS: use of the experimental drug 9-(1,3-Dihydroxy-2-Propoxymethyl) guanine
112. Development of vaccine against mental retardation caused by cytomegalovirus infection in utero
113. Candidate cytomegalovirus strain for human vaccination
114. Prevention and treatment of cytomegalovirus infection
115. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus
116. Live cytomegalovirus vaccination of healthy volunteers
117. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine
118. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial
119. Selection of particles and proteins for use as human cytomegalovirus subunit vaccines
120. Cell surface expression of human cytomegalovirus gP55–116 (gB): Use of HCMV-recombinant vaccinia virus-infected cells in analysis of human neutralizing antibody response
121. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies